{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T21:31:31Z","timestamp":1792359091982,"version":"4.4.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,8]]},"DOI":"10.7759\/cureus.71050","type":"journal-article","created":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T07:18:40Z","timestamp":1728371920000},"source":"Crossref","is-referenced-by-count":2,"title":["Concurrent Primary Cutaneous Cryptococcosis and Bowen's Disease in a Patient With Multiple Sclerosis on Fingolimod: A Rare Case Report and Review of Literature"],"prefix":"10.7759","author":[{"given":"Gullu","family":"Gencebay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nisan","family":"\u00c7etin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melin","family":"Gecer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozlem","family":"Su Kucuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02669","article-title":"Real world lab data: patterns of lymphocyte counts in fingolimod treated patients","volume":"9","author":"Kaufmann M","year":"2018","unstructured":"Kaufmann M, Haase R, Proschmann U, Ziemssen T, Akg\u00fcn K. Real world lab data: patterns of lymphocyte counts in fingolimod treated patients. Front Immunol. 2018, 9:2669. 10.3389\/fimmu.2018.02669","journal-title":"Front Immunol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2017.1373093","article-title":"Fingolimod hydrochloride for the treatment of relapsing remitting multiple sclerosis","volume":"18","author":"Thomas K","year":"2017","unstructured":"Thomas K, Proschmann U, Ziemssen T. Fingolimod hydrochloride for the treatment of relapsing remitting multiple sclerosis. Expert Opin Pharmacother. 2017, 18:1649-60. 10.1080\/14656566.2017.1373093","journal-title":"Expert Opin Pharmacother"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-023-07075-2","article-title":"Letter to the editors: development of malignant melanoma and squamous cell carcinoma in a patient receiving fingolimod treatment","volume":"45","author":"Karabas M","year":"2024","unstructured":"Karabas M, Tepe N, Esmeli F. Letter to the editors: development of malignant melanoma and squamous cell carcinoma in a patient receiving fingolimod treatment. Neurol Sci. 2024, 45:359-60. 10.1007\/s10072-023-07075-2","journal-title":"Neurol Sci"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s11046-015-9880-7","article-title":"Systemic review of published reports on primary cutaneous cryptococcosis in immunocompetent patients","volume":"180","author":"Du L","year":"2015","unstructured":"Du L, Yang Y, Gu J, Chen J, Liao W, Zhu Y. Systemic review of published reports on primary cutaneous cryptococcosis in immunocompetent patients. Mycopathologia. 2015, 180:19-25. 10.1007\/s11046-015-9880-7","journal-title":"Mycopathologia"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.abd.2020.12.004","article-title":"Primary cutaneous cryptococcosis: the importance of early diagnosis","volume":"96","author":"Silva Souza CD","year":"2021","unstructured":"Silva Souza CD, Takada MH, Ambiel MV, Nakai VT. Primary cutaneous cryptococcosis: the importance of early diagnosis. An Bras Dermatol. 2021, 96:482-4. 10.1016\/j.abd.2020.12.004","journal-title":"An Bras Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-021-10931-w","article-title":"Long-term real-world effectiveness and safety of fingolimod over 5\u00a0years in Germany","volume":"269","author":"Ziemssen T","year":"2022","unstructured":"Ziemssen T, Lang M, Schmidt S, et al.. Long-term real-world effectiveness and safety of fingolimod over 5\u00a0years in Germany. J Neurol. 2022, 269:3276-85. 10.1007\/s00415-021-10931-w","journal-title":"J Neurol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2015.4259","article-title":"Primary cutaneous Cryptococcus in a patient with multiple sclerosis treated with fingolimod","volume":"73","author":"Forrestel AK","year":"2016","unstructured":"Forrestel AK, Modi BG, Longworth S, Wilck MB, Micheletti RG. Primary cutaneous Cryptococcus in a patient with multiple sclerosis treated with fingolimod. JAMA Neurol. 2016, 73:355-6. 10.1001\/jamaneurol.2015.4259","journal-title":"JAMA Neurol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.idcr.2020.e00810","article-title":"Primary cutaneous cryptococcal infection due to fingolimod - Induced lymphopenia with literature review","volume":"21","author":"Patil SM","year":"2020","unstructured":"Patil SM, Beck PP, Arora N, Acevedo BA, Dandachi D. Primary cutaneous cryptococcal infection due to fingolimod - Induced lymphopenia with literature review. IDCases. 2020, 21:e00810. 10.1016\/j.idcr.2020.e00810","journal-title":"IDCases"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3314\/mmj.19.008","article-title":"Cutaneous cryptococcosis","volume":"60","author":"Noguchi H","year":"2019","unstructured":"Noguchi H, Matsumoto T, Kimura U, Hiruma M, Kusuhara M, Ihn H. Cutaneous cryptococcosis. Med Mycol J. 2019, 60:101-7. 10.3314\/mmj.19.008","journal-title":"Med Mycol J"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.16444","article-title":"Primary cutaneous cryptococcosis in a patient on fingolimod: a case report","volume":"13","author":"Dahshan D","year":"2021","unstructured":"Dahshan D, Dessie SA, Cuda J, Khalil E. Primary cutaneous cryptococcosis in a patient on fingolimod: a case report. Cureus. 2021, 13:e16444. 10.7759\/cureus.16444","journal-title":"Cureus"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1177\/1756286419878324","article-title":"Extended treatment with fingolimod for relapsing multiple sclerosis: the 14-year LONGTERMS study results","volume":"12","author":"Cohen JA","year":"2019","unstructured":"Cohen JA, Tenenbaum N, Bhatt A, Zhang Y, Kappos L. Extended treatment with fingolimod for relapsing multiple sclerosis: the 14-year LONGTERMS study results. Ther Adv Neurol Disord. 2019, 12:1756286419878324. 10.1177\/1756286419878324","journal-title":"Ther Adv Neurol Disord"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.36740\/WLek202203129","article-title":"Basal cell carc\u0131noma and squamous cell carc\u0131noma \u0131n a pat\u0131ent treated w\u0131th f\u0131ngol\u0131mod for mult\u0131ple scleros\u0131s - a case report and l\u0131terature rev\u0131ew","volume":"75","author":"Zi\u0119ba N","year":"2022","unstructured":"Zi\u0119ba N, G\u0119bka-K\u0119pi\u0144ska B, Sowa P. Basal cell carc\u0131noma and squamous cell carc\u0131noma \u0131n a pat\u0131ent treated w\u0131th f\u0131ngol\u0131mod for mult\u0131ple scleros\u0131s - a case report and l\u0131terature rev\u0131ew. Wiad Lek. 2022, 75:735-41. 10.36740\/WLek202203129","journal-title":"Wiad Lek"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2019.03.011","article-title":"Melanoma during fingolimod treatment for multiple sclerosis","volume":"113","author":"Velter C","year":"2019","unstructured":"Velter C, Thomas M, Cavalcanti A, et al.. Melanoma during fingolimod treatment for multiple sclerosis. Eur J Cancer. 2019, 113:75-7. 10.1016\/j.ejca.2019.03.011","journal-title":"Eur J Cancer"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2024.07.007","article-title":"Risk of skin cancer associated with disease-modifying therapies in multiple sclerosis: a modern comprehensive evidence review","author":"Brufau-Cochs M","year":"2024","unstructured":"Brufau-Cochs M, Mansilla-Polo M, Morgado-Carrasco D. Risk of skin cancer associated with disease-modifying therapies in multiple sclerosis: a modern comprehensive evidence review. Actas Dermosifiliogr. 2024, 10.1016\/j.ad.2024.07.007","journal-title":"Actas Dermosifiliogr"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/300446-concurrent-primary-cutaneous-cryptococcosis-and-bowens-disease-in-a-patient-with-multiple-sclerosis-on-fingolimod-a-rare-case-report-and-review-of-literature","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T07:18:44Z","timestamp":1728371924000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/300446-concurrent-primary-cutaneous-cryptococcosis-and-bowens-disease-in-a-patient-with-multiple-sclerosis-on-fingolimod-a-rare-case-report-and-review-of-literature"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,8]]},"references-count":14,"URL":"https:\/\/doi.org\/10.7759\/cureus.71050","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,8]]}}}